Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis.

Harry K W Kim1, Stephanie Morgan-Bagley, Paul Kostenuik

  • 1Center for Research in Skeletal Development and Pediatric Orthopaedics, Shriners Hospitals for Children, FL 33612, USA. hkim@shrinenet.org

Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|September 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relaxation Time Mapping of Early-Stage Osteonecrosis of the Femoral Head: An In Vivo Piglet Model Study.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society·2026
Same author

Longitudinal Quality of Life Outcomes in Children Treated With Petrie Casting and Wide-abduction Bracing for Legg-Calve-Perthes Disease.

Journal of pediatric orthopedics·2026
Same author

Impact of Legg-Calvé-Perthes Disease on Physical, Mental, and Social Health in Children Aged 6 to 11 Years at Diagnosis-an Assessment Using PROMIS.

Journal of pediatric orthopedics·2026
Same author

Improved Gait and Patient-Reported Outcomes Following Hip Preservation Procedures Via Surgical Hip Dislocation Approach in Adolescents With Residual Legg-Calvé-Perthes Disease.

Journal of pediatric orthopedics·2026
Same author

Longitudinal Computed Tomographic Evaluation of Mandibular Bone Morphology Following OnabotulinumtoxinA Treatment of Masseter Muscle Prominence: Results of a 12-Month, Repeat-Treatment, Placebo-Controlled Study in Healthy Adults.

Aesthetic surgery journal·2026
Same author

Hip Osteonecrosis in Sickle Cell Disease Patient With Severe Central Head Collapse Treated With Staged Hip Preservation: A Case Report.

JBJS case connector·2026

RANKL inhibition using osteoprotegerin (OPG-Fc) significantly reduced bone resorption and femoral head deformity in an animal model of ischemic osteonecrosis. This novel therapeutic strategy shows promise for treating conditions like Legg-Calvé-Perthes disease.

Area of Science:

  • Orthopedics
  • Bone Biology
  • Pharmacology

Background:

  • Legg-Calvé-Perthes disease (LCPD) causes femoral head deformity (FHD) and osteoarthritis in children.
  • FHD development is linked to excessive bone resorption during the repair of ischemic osteonecrosis.
  • A large animal model of ischemic osteonecrosis was used to test a new treatment strategy.

Purpose of the Study:

  • To evaluate the efficacy of RANKL inhibition in preventing femoral head deformity after ischemic osteonecrosis.
  • To assess the impact of osteoprotegerin (OPG-Fc) on bone resorption and structural integrity during the repair process.

Main Methods:

  • Surgical induction of ischemic osteonecrosis in the femoral head of 18 piglets.
  • Subcutaneous administration of OPG-Fc or saline for 6 weeks, starting 2 weeks post-induction.

Related Experiment Videos

  • Radiographic, histomorphometric, and immunohistochemical analyses were performed at 8 weeks.

    • Main Results:

    • OPG-Fc treatment significantly preserved femoral head structure compared to saline controls.
    • The epiphyseal quotient was significantly higher in the OPG-Fc group (0.41 vs. 0.24).
    • Osteoclast numbers were significantly reduced (5.9 vs. 39.6 mm(-2)), and trabecular bone was better preserved with OPG-Fc.

    Conclusions:

    • RANKL inhibition effectively decreases bone resorption and prevents femoral head deformity post-ischemic osteonecrosis.
    • The reversible nature of RANKL inhibitors makes them suitable for treating pediatric bone diseases like LCPD.
    • This study is the first to demonstrate RANKL inhibition's efficacy in reducing bone resorption and FHD in this context.